Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Radiochimica Acta

International Journal for chemical aspects of nuclear science and technology

Editor-in-Chief: Qaim, Syed M.

12 Issues per year


IMPACT FACTOR 2017: 1.202

CiteScore 2017: 1.22

SCImago Journal Rank (SJR) 2017: 0.409
Source Normalized Impact per Paper (SNIP) 2017: 0.869

Online
ISSN
2193-3405
See all formats and pricing
More options …
Volume 90, Issue 5

Issues

Production routes of the alpha emitting 149Tb for medical application

G. J. Beyer / J. J. Čomor / M. Daković / D. Soloviev / C. Tamburella / E. Hagebø / B. Allan / S. N. Dmitriev / N. G. Zaitseva /
Published Online: 2009-09-25 | DOI: https://doi.org/10.1524/ract.2002.90.5_2002.247

Summary

The partial alpha emitting lanthanide isotope 149Tb seems to have a great potential in systemic radioimmuno therapy (RIT), especially when single cells in transit or circulation are targeted. The isotope 149Tb has a half life of 4.118 h and decays by alpha emission (3.97 MeV, 17%) EC-process (76%) and β+-emission (7%). In this paper, we analyze the possible production routes: light- and heavy ion induced nuclear reactions and p-induced spallation.

The excitation functions for light- and heavy ion induced reactions have been calculated using the ALICE91 code. The direct nuclear reaction 152Gd (p, 4n) 149Tb was found to be the most promising production path. Alternatively, the indirect reaction 142Nd (12C, 5n) 149Dy → 149Tb seems to be much more suitable compared to the reaction on the mono-isotopic target element 141Pr 12C, 4n) 149Tb. In this case, both, the production yield of 149Tb and the radionuclidic purity are considerably lower, compared to the (p, 4n)-reaction. In preliminary experiments we produced 149Tb via the indirect reaction Nd (12C, 5n) 149Dy → 149Tb (108 MeV 12C+6 ions and 1 particle-µA) at the U-200 heavy ion cyclotron at the FLNR of the JINR Dubna. From a 1.25 h irradiation of a 12 mg/cm2natNd2O3 target, we obtained 2.7 MBq of 149Tb (70 µCi) at 20 min EOB. This allows the conclusion, that a dedicated cyclotron equipped with a modern ECR-ion source, providing high ion currents would allow the continuous production of batches of the order of 10–20 GBq of 149Tb for routine RI-therapy.

The lower cross section of the spallation process can be compensated by using very thick targets. On-line mass separation technique provides high purity isotopically clean 149Tb preparations, independently on the production route chosen. At the ISOLDE facility at CERN, we prepared batches of up to 500 MBq 149Tb by combining on-line mass separation process followed by a cation exchange chromatography process using α-HIBA as eluent. The obtained 149Tb preparations showed excellent behavior in labeling of chelated monoclonal antibodies.

About the article

Received: 2001-04-05

Accepted: 2001-11-07

Published Online: 2009-09-25

Published in Print: 2002-05-01


Citation Information: Radiochimica Acta, Volume 90, Issue 5, Pages 247–252, ISSN (Online) 2193-3405, ISSN (Print) 0033-8230, DOI: https://doi.org/10.1524/ract.2002.90.5_2002.247.

Export Citation

© Oldenbourg Wissenschaftsverlag, München.Get Permission

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

[1]
[2]
Syed M. Qaim, Bernhard Scholten, and Bernd Neumaier
Journal of Radioanalytical and Nuclear Chemistry, 2018
[3]
N. N. Il’inskaya, T. Yu. Malamut, and A. A. Ogloblin
JETP Letters, 2018
[4]
Cristina Müller, Katharina A Domnanich, Christoph A Umbricht, and Nicholas P van der Meulen
The British Journal of Radiology, 2018, Page 20180074
[5]
Johannes Notni and Hans-Jürgen Wester
Journal of Labelled Compounds and Radiopharmaceuticals, 2018, Volume 61, Number 3, Page 141
[6]
Ján Kozempel, Olga Mokhodoeva, and Martin Vlk
Molecules, 2018, Volume 23, Number 3, Page 581
[7]
Cristina Müller, Josefine Reber, Stephanie Haller, Holger Dorrer, Ulli Köster, Karl Johnston, Konstantin Zhernosekov, Andreas Türler, and Roger Schibli
Pharmaceuticals, 2014, Volume 7, Number 12, Page 353
[9]
Cristina Müller, Christiaan Vermeulen, Karl Johnston, Ulli Köster, Raffaella Schmid, Andreas Türler, and Nicholas P. van der Meulen
EJNMMI Research, 2016, Volume 6, Number 1
[10]
Mark Woods, Zoltan Kovacs, and A.Dean Sherry
Journal of Supramolecular Chemistry, 2002, Volume 2, Number 1-3, Page 1
[11]
Gerd J. Beyer and Thomas J. Ruth
Nuclear Instruments and Methods in Physics Research Section B: Beam Interactions with Materials and Atoms, 2003, Volume 204, Page 694
[13]
Moumita Maiti, Susanta Lahiri, and B. S. Tomar
Radiochimica Acta, 2011, Volume 99, Number 9, Page 527
[14]
Matthias Miederer, Christof Seidl, Gerd-Jürgen Beyer, David E. Charlton, Sanja Vranjes-Duric, Jozef J. Comor, Roswitha Huber, Tuomo Nikula, Christos Apostolidis, Christoph Schuhmacher, Karl-Friedrich Becker, and Reingard Senekowitsch-Schmidtke
Radiation Research, 2003, Volume 159, Number 5, Page 612
[15]
G. J. Beyer, S. K. Zeisler, and D. W. Becker
Radiochimica Acta, 2004, Volume 92, Number 4-6
[16]
S. N. Dmitriev and N. G. Zaitseva
Radiochimica Acta, 2005, Volume 93, Number 9-10
[17]
N. G. Zaitseva, S. N. Dmitriev, O. D. Maslov, L. G. Molokanova, G. Ya. Starodub, S. V. Shishkin, T. V. Shishkina, and G. J. Beyer
Czechoslovak Journal of Physics, 2003, Volume 53, Number S1, Page A455
[18]
Martin W. Brechbiel
Dalton Transactions, 2007, Number 43, Page 4918
[19]
G.-J. Beyer, M. Miederer, S. Vranješ-Đurić, J. J. Čomor, G. Künzi, O. Hartley, R. Senekowitsch-Schmidtke, D. Soloviev, and F. Buchegger
European Journal of Nuclear Medicine and Molecular Imaging, 2004, Volume 31, Number 4, Page 547
[20]
Barry J Allen
Physics in Medicine and Biology, 2006, Volume 51, Number 13, Page R327

Comments (0)

Please log in or register to comment.
Log in